Dalbavancin as sequential therapy for infective endocarditis due to Gram-positive organisms: a review

Link to article at PubMed

Int J Antimicrob Agents. 2023 Apr;61(4):106749. doi: 10.1016/j.ijantimicag.2023.106749. Epub 2023 Feb 8.


Dalbavancin is a parenteral lipoglycopeptide antibiotic derived from teicoplanin, an analogue of vancomycin. It is mainly used for skin and soft tissue infections. The sustained half-life of approximately 14 days makes dalbavancin a novel option for potential use as sequential treatment in infections such as infective endocarditis, which require prolonged antibiotic courses. However, only a few studies have been reported in the literature, and the use of dalbavancin remains limited. This article is a review of the currently available literature using dalbavancin for the treatment of infective endocarditis due to Gram-positive organisms. Almost all patients received dalbavancin as sequential therapy following standard-of-care antibiotics. The overall clinical efficacy of dalbavancin was approximately 90%, and it appeared to be well tolerated.

PMID:36758775 | DOI:10.1016/j.ijantimicag.2023.106749

Leave a Reply

Your email address will not be published. Required fields are marked *